Search

Your search keyword '"Asmis T"' showing total 152 results
Start Over Author "Asmis T"
152 results on '"Asmis T"'

10. Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care

Author

Woodhouse, B, Pattison, S, Segelov, E, Singh, S, Parker, K, Kong, G, Macdonald, W, Wyld, D, Meyer-Rochow, G, Pavlakis, N, Conroy, S, Gordon, V, Koea, J, Kramer, N, Michael, M, Wakelin, K, Asif, T, Lo, D, Price, T, Lawrence, B, Anaka, M, Asmis, T, Asselah, J, Boekhoud, J, Card, C, Carroll, R, Cehic, G, Chaudhury, P, Corsini, N, Elston, M, Goodwin, R, Gould, A, Gray, D, Hayes, A, Kevat, D, Laidley, D, Law, C, Leyden, S, Love, A, Mandarino, E, Marginean, C, Modahl, L, Mumford, J, Myrehaug, S, O'Callaghan, C, Patel, D, Ransom, D, Roach, P, Strickland, A, Thawer, A, Vickers, M, Wieler, M, Xu, B, Yelamanchili, R, Woodhouse, B, Pattison, S, Segelov, E, Singh, S, Parker, K, Kong, G, Macdonald, W, Wyld, D, Meyer-Rochow, G, Pavlakis, N, Conroy, S, Gordon, V, Koea, J, Kramer, N, Michael, M, Wakelin, K, Asif, T, Lo, D, Price, T, Lawrence, B, Anaka, M, Asmis, T, Asselah, J, Boekhoud, J, Card, C, Carroll, R, Cehic, G, Chaudhury, P, Corsini, N, Elston, M, Goodwin, R, Gould, A, Gray, D, Hayes, A, Kevat, D, Laidley, D, Law, C, Leyden, S, Love, A, Mandarino, E, Marginean, C, Modahl, L, Mumford, J, Myrehaug, S, O'Callaghan, C, Patel, D, Ransom, D, Roach, P, Strickland, A, Thawer, A, Vickers, M, Wieler, M, Xu, B, and Yelamanchili, R

Abstract

Quality performance indicators (QPIs) are used to monitor the delivery of cancer care. Neuroendocrine tumours (NETs) are a family of individually uncommon cancers that derive from neuroendocrine cells or their precursors, and can occur in most organs. There are currently no QPIs available for NETs and their heterogeneity makes QPI development difficult. CommNETs is a collaboration between NET clinicians, researchers and advocates in Canada, Australia and New Zealand. We created QPIs for NETs using a three-step consensus process. First, a multidisciplinary team used the nominal group technique to create candidates (n = 133) which were then curated into appropriateness statements (62 statements, 44 sub-statements). A two-stage modified RAND/UCLA Delphi consensus process was conducted: an online survey rated the statement appropriateness then the top-ranked statements (n = 20) were assessed in a face-to-face meeting. Finally, 10 QPIs met consensus criteria; documentation of primary site, proliferative index, differentiation, tumour board review, use of a structured pathology report, presence of distant metastasis, 5- and 10-year disease-free and overall survival. These NET QPIs will be trialed as a method to monitor and improve care for people with NETs and to facilitate international comparison.

Published
2019

14. Eastern Canadian Colorectal Cancer Consensus Conference 2017

Author

McGee, S. F., primary, AlGhareeb, W., additional, Ahmad, C. H., additional, Armstrong, D., additional, Babak, S., additional, Berry, S., additional, Biagi, J., additional, Booth, C., additional, Bossé, D., additional, Champion, P., additional, Colwell, B., additional, Finn, N., additional, Goel, R., additional, Gray, S., additional, Green, J., additional, Harb, M., additional, Hyde, A., additional, Jeyakumar, A., additional, Jonker, D., additional, Kanagaratnam, S., additional, Kavan, P., additional, MacMillan, A., additional, Muinuddin, A., additional, Patil, N., additional, Porter, G., additional, Powell, E., additional, Ramjeesingh, R., additional, Raza, M., additional, Rorke, S., additional, Seal, M., additional, Servidio-Italiano, F., additional, Siddiqui, J., additional, Simms, J., additional, Smithson, L., additional, Snow, S., additional, St-Hilaire, E., additional, Stuckless, T., additional, Tate, A., additional, Tehfe, M., additional, Thirlwell, M., additional, Tsvetkova, E., additional, Valdes, M., additional, Vickers, M., additional, Virik, K., additional, Welch, S., additional, Marginean, C., additional, and Asmis, T., additional

Published
2018
Full Text
View/download PDF

15. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Author

Yao, James C, Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward, Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Pacaud, Lida Bubuteishvili, Rouyrre, Nicolas, Sachs, Carolin, Valle, Juan W, Delle Fave, Gianfranco, Van Cutsem, Eric, Tesselaar, Margot, Shimada, Yasuhiro, Oh, Do-Youn, Strosberg, Jonathan, Kulke, Matthew H, Pavel, Marianne E, Raderer, M, Pall, G, Van Cutsem, E, Borbath, I, Geboes, K, Peeters, M, Asmis, T, Kocha, W, Rayson, D, Ruether, J, Singh, S, Sideris, L, Kennecke, H, Wang, J, Shen, L, Xu, J, Qian, J, Jia, L, Maya, L F, Melichar, B, Sedlackova, E, Tomasek, J, Pavel, M, Bojunga, J, Malfertheiner, P, Vogel, A, Weber, M, Hörsch, D, Kaltsas, G, Papai, Z, Toth, M, Carnaghi, C, Luppi, G, Fazio, N, Tomassetti, P, Delle Fave, G, Cartenì, G, Buzzoni, R, Barone, C, Berruti, A, Giuffrida, D, Tortora, G, Di Costanzo, F, Tafuto, S, Ito, T, Okita, N, Komoto, I, Kattan, J, Shamseddine, A, Tesselaar, M, Jarzab, B, Ruchala, M, Vladimirova, L, Raef, H, Salek, T, Ruff, P, Kim, T W, Park, Y S, Oh, D-Y, Lee, M-A, Choi, H J, Capdevila, J, Salazar, R, Zoilo, J J R, Chen, J-S, Wu, C-C, Chen, Y-Y, Chao, Y, Yeh, K-H, Sriuranpong, V, Thongprasert, S, Turna, H, Sevinc, A, Valle, J, Sarker, D, Reed, N, Cave, J, Frilling, A, Corrie, P, Fanta, P, Yao, J, Strosberg, J, Verma, U, Libutti, S, Natale, R, Pommier, R, Lubner, S, Starodub, A, Kulke, M, Sigal, D, Polite, B, Lieu, C, Hande, K, Reidy-Lagunes, D, McCollum, A, and Forero, L

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Lung Neoplasms, Medizin, Antineoplastic Agents, Neuroendocrine tumors, Placebo, Gastroenterology, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Clinical endpoint, Humans, Everolimus, Aged, Gastrointestinal Neoplasms, Aged, 80 and over, Performance status, business.industry, Sunitinib, Medicine (all), Hazard ratio, General Medicine, Middle Aged, medicine.disease, Survival Analysis, 3. Good health, Surgery, Neuroendocrine Tumors, 030104 developmental biology, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Female, business, medicine.drug
Abstract

Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population.In the randomised, double-blind, placebo-controlled, phase 3 RADIANT-4 trial, adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled from 97 centres in 25 countries worldwide. Eligible patients were randomly assigned in a 2:1 ratio by an interactive voice response system to receive everolimus 10 mg per day orally or identical placebo, both with supportive care. Patients were stratified by tumour origin, performance status, and previous somatostatin analogue treatment. Patients, investigators, and the study sponsor were masked to treatment assignment. The primary endpoint was progression-free survival assessed by central radiology review, analysed by intention to treat. Overall survival was a key secondary endpoint. This trial is registered with ClinicalTrials.gov, number NCT01524783.Between April 3, 2012, and Aug 23, 2013, a total of 302 patients were enrolled, of whom 205 were allocated to everolimus 10 mg per day and 97 to placebo. Median progression-free survival was 11·0 months (95% CI 9·2-13·3) in the everolimus group and 3·9 months (3·6-7·4) in the placebo group. Everolimus was associated with a 52% reduction in the estimated risk of progression or death (hazard ratio [HR] 0·48 [95% CI 0·35-0·67], p0·00001). Although not statistically significant, the results of the first pre-planned interim overall survival analysis indicated that everolimus might be associated with a reduction in the risk of death (HR 0·64 [95% CI 0·40-1·05], one-sided p=0·037, whereas the boundary for statistical significance was 0·0002). Grade 3 or 4 drug-related adverse events were infrequent and included stomatitis (in 18 [9%] of 202 patients in the everolimus group vs 0 of 98 in the placebo group), diarrhoea (15 [7%] vs 2 [2%]), infections (14 [7%] vs 0), anaemia (8 [4%] vs 1 [1%]), fatigue (7 [3%] vs 1 [1%]), and hyperglycaemia (7 [3%] vs 0).Treatment with everolimus was associated with significant improvement in progression-free survival in patients with progressive lung or gastrointestinal neuroendocrine tumours. The safety findings were consistent with the known side-effect profile of everolimus. Everolimus is the first targeted agent to show robust anti-tumour activity with acceptable tolerability across a broad range of neuroendocrine tumours, including those arising from the pancreas, lung, and gastrointestinal tract.Novartis Pharmaceuticals Corporation.

Published
2015

18. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Author

Moore, M., primary, Gill, S., additional, Asmis, T., additional, Berry, S., additional, Burkes, R., additional, Zbuk, K., additional, Alcindor, T., additional, Jeyakumar, A., additional, Chan, T., additional, Rao, S., additional, Spratlin, J., additional, Tang, P.A., additional, Rothenstein, J., additional, Chan, E., additional, Bendell, J., additional, Kudrik, F., additional, Kauh, J., additional, Tang, S., additional, Gao, L., additional, Kambhampati, S.R.P., additional, Nasroulah, F., additional, Yang, L., additional, Ramdas, N., additional, Binder, P., additional, and Strevel, E., additional

Published
2016
Full Text
View/download PDF

19. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Author

Bossé, D., primary, Ng, T., additional, Ahmad, C., additional, Alfakeeh, A., additional, Alruzug, I., additional, Biagi, J., additional, Brierley, J., additional, Chaudhury, P., additional, Cleary, S., additional, Colwell, B., additional, Cripps, C., additional, Dawson, L.A., additional, Dorreen, M., additional, Ferland, E., additional, Galiatsatos, P., additional, Girard, S., additional, Gray, S., additional, Halwani, F., additional, Kopek, N., additional, Mahmud, A., additional, Martel, G., additional, Robillard, L., additional, Samson, B., additional, Seal, M., additional, Siddiqui, J., additional, Sideris, L., additional, Snow, S., additional, Thirwell, M., additional, Vickers, M., additional, Goodwin, R., additional, Goel, R., additional, Hsu, T., additional, Tsvetkova, E., additional, Ward, B., additional, and Asmis, T., additional

Published
2016
Full Text
View/download PDF

21. Corrigendum: Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014

Author

Tsvetkova, E., primary, Sud, S., additional, Aucoin, N., additional, Biagi, J., additional, Burkes, R., additional, Samson, B., additional, Brule, S., additional, Cripps, C., additional, Colwell, B., additional, Falkson, C., additional, Dorreen, M., additional, Goel, R., additional, Halwani, F., additional, Marginean, C., additional, Maroun, J., additional, Michaud, N., additional, Tehfe, M., additional, Thirlwell, M., additional, Vickers, M., additional, and Asmis, T., additional

Published
2016
Full Text
View/download PDF

23. Eastern Canadian Colorectal Cancer Consensus Conference 2013: Emerging Therapies in the Treatment of Pancreatic, Rectal, and Colorectal Cancers

Author

Di Valentin, T., primary, Asmis, T., additional, Asselah, J., additional, Aubin, F., additional, Aucoin, N., additional, Berry, S., additional, Biagi, J., additional, Booth, C.M., additional, Burkes, R., additional, Coburn, N., additional, Colwell, B., additional, Cripps, C., additional, Dawson, L.A., additional, Dorreen, M., additional, Frechette, D., additional, Goel, R., additional, Gray, S., additional, Hammad, N., additional, Jonker, D., additional, Kavan, P., additional, Maroun, J., additional, Nanji, S., additional, Roberge, D., additional, Samson, B., additional, Seal, M., additional, Shabana, W., additional, Simunovic, M., additional, Snow, S., additional, Tehfe, M., additional, Thirlwell, M., additional, Tsvetkova, E., additional, Vickers, M., additional, Vuong, T., additional, and Goodwin, R., additional

Published
2016
Full Text
View/download PDF

24. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial

Author

Horgan, A. M, primary, Darling, G., additional, Wong, R., additional, Guindi, M., additional, Liu, G., additional, Jonker, D. J., additional, Lister, J., additional, Xu, W., additional, MacKay, H. M., additional, Dinniwell, R., additional, Kim, J., additional, Pierre, A., additional, Shargall, Y., additional, Asmis, T. R., additional, Agboola, O., additional, Seely, A. J., additional, Ringash, J., additional, Wells, J., additional, Marginean, E. C., additional, Haider, M., additional, and Knox, J. J., additional

Published
2015
Full Text
View/download PDF

25. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014

Author

Tsvetkova, E., primary, Sud, S., additional, Aucoin, N., additional, Biagi, J., additional, Burkes, R., additional, Samson, B., additional, Brule, S., additional, Cripps, C., additional, Colwell, B., additional, Falkson, C., additional, Dorreen, M., additional, Goel, R., additional, Halwani, F., additional, Maroun, J., additional, Michaud, N., additional, Tehfe, M., additional, Thirlwell, M., additional, Vickers, M., additional, and Asmis, T., additional

Published
2015
Full Text
View/download PDF

28. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.

Author

Horgan, A. M., Darling, G., Wong, R., Guindi, M., Liu, G., Jonker, D. J., Lister, J., Xu, W., MacKay, H. M., Dinniwell, R., Kim, J., Pierre, A., Shargall, Y., Asmis, T. R., Agboola, O., Seely, A. J., Ringash, J., Wells, J., Marginean, E. C., and Haider, M.

Subjects
ESOPHAGEAL cancer, CHEMORADIOTHERAPY, OPERATIVE surgery, ESOPHAGOGASTRIC junction, IRINOTECAN
Abstract

The prognosis for locally advanced esophageal cancer is poor despite the use of trimodality therapy. In this phase II study, we report the feasibility, tolerability and efficacy of adjuvant sunitinib. Included were patients with stage IIa, IIB or III cancer of the thoracic esophagus or gastroesophageal junction. Neoadjuvant therapy involved Irinotecan (65 mg/m2) + Cisplatin (30 mg/m2) on weeks 1 and 2, 4 and 5, 7 and 8 with concurrent radiation (50 Gy/25 fractions) on weeks 4-8. Sunitinib was commenced 4-13 weeks after surgery and continued for one year. Sixty-one patients were included in the final analysis, 36 patients commenced adjuvant sunitinib. Fourteen patients discontinued sunitinib due to disease recurrence (39%) within the 12-month period, 12 (33%) discontinued due to toxicity, and 3 (8%) requested cessation of therapy. In the overall population, median survival was 26 months with a 2 and 3-year survival rate of 52% and 35%, respectively. The median survival for the 36 patients treated with sunitinib was 35 months and 2-year survival probability of 68%. In a historical control, a prior phase II study with the same trimodality therapy (n = 43), median survival was 36 months, with a 2-year survival of 67%. Initiation of adjuvant sunitinib is feasible, but poorly tolerated, with no signal of additional benefit over trimodality therapy for locally advanced esophageal cancer. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

30. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement

Author

Karanicolas, P.J., primary, Metrakos, P., additional, Chan, K., additional, Asmis, T., additional, Chen, E., additional, Kingham, T.P., additional, Kemeny, N., additional, Porter, G., additional, Fields, R.C., additional, Pingpank, J., additional, Dixon, E., additional, Wei, A., additional, Cleary, S., additional, Zogopoulos, G., additional, Dey, C., additional, D'Angelica, M., additional, Fong, Y., additional, Dowden, S., additional, and Ko, Y.J., additional

Published
2013
Full Text
View/download PDF

32. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.

Author

Horgan, A. M, Darling, G., Wong, R., Guindi, M., Liu, G., Jonker, D. J., Lister, J., Xu, W., MacKay, H. M., Dinniwell, R., Kim, J., Pierre, A., Shargall, Y., Asmis, T. R., Agboola, O., Seely, A. J., Ringash, J., Wells, J., Marginean, E. C., and Haider, M.

Subjects
TREATMENT of esophageal cancer, ADJUVANT treatment of cancer, CHEMORADIOTHERAPY, ESOPHAGEAL cancer, ESOPHAGOGASTRIC junction, CLINICAL trials, PROGNOSIS
Abstract

The prognosis for locally advanced esophageal cancer is poor despite the use of trimodality therapy. In this phase II study, we report the feasibility, tolerability and efficacy of adjuvant sunitinib. Included were patients with stage IIa, IIB or III cancer of the thoracic esophagus or gastroesophageal junction. Neoadjuvant therapy involved Irinotecan (65 mg/m2) + Cisplatin (30 mg/m2) on weeks 1 and 2, 4 and 5, 7 and 8 with concurrent radiation (50 Gy/25 fractions) on weeks 4-8. Sunitinib was commenced 4-13 weeks after surgery and continued for one year. Sixty-one patients were included in the final analysis, 36 patients commenced adjuvant sunitinib. Fourteen patients discontinued sunitinib due to disease recurrence (39%) within the 12-month period, 12 (33%) discontinued due to toxicity, and 3 (8%) requested cessation of therapy. In the overall population, median survival was 26 months with a 2 and 3-year survival rate of 52% and 35%, respectively. The median survival for the 36 patients treated with sunitinib was 35 months and 2-year survival probability of 68%. In a historical control, a prior phase II study with the same trimodality therapy ( n = 43), median survival was 36 months, with a 2-year survival of 67%. Initiation of adjuvant sunitinib is feasible, but poorly tolerated, with no signal of additional benefit over trimodality therapy for locally advanced esophageal cancer. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

34. Eastern Canadian Colorectal Cancer Consensus Conference: Application of New Modalities of Staging and Treatment of Gastrointestinal Cancers

Author

Di Valentin, T., primary, Alam, Y., additional, Alsharm, A. Ali, additional, Arif, S., additional, Aubin, F., additional, Biagi, J., additional, Booth, C.M., additional, Bourque, S., additional, Burkes, R., additional, Champion, P., additional, Colwell, B., additional, Cripps, C., additional, Dallaire, M., additional, Dorreen, M., additional, Finn, N., additional, Frechette, D., additional, Gallinger, S., additional, Gapski, J., additional, Giacomantonio, C., additional, Gill, S., additional, Goel, R., additional, Goodwin, R., additional, Grimard, L., additional, Grothey, A., additional, Hammad, N., additional, Hedley, D., additional, Jhaveri, K., additional, Jonker, D., additional, Ko, Y., additional, L’Espérance, M., additional, Maroun, J., additional, Ostic, H., additional, Perrin, N., additional, Rother, M., additional, St-Hilaire, E., additional, Tehfe, M., additional, Thirlwell, M., additional, Welch, S., additional, Yarom, N., additional, and Asmis, T., additional

Published
2012
Full Text
View/download PDF

36. Eastern Canadian Colorectal Cancer Consensus Conference: Setting the Limits of Resectable Disease

Author

Vickers, M., primary, Samson, B., additional, Colwell, B., additional, Cripps, C., additional, Jalink, D., additional, El-Sayed, S., additional, Chen, E., additional, Porter, G., additional, Goel, R., additional, Villeneuve, J., additional, Sundaresan, S., additional, Asselah, J., additional, Biagi, J., additional, Jonker, D., additional, Dawson, L., additional, Letourneau, R., additional, Rother, M., additional, Maroun, J., additional, Thirlwell, M., additional, Hussein, M., additional, Tehfe, M., additional, Perrin, N., additional, Michaud, N., additional, Hammad, N., additional, Champion, P., additional, Rajan, R., additional, Burkes, R., additional, Barrette, S., additional, Welch, S., additional, Yarom, N., additional, and Asmis, T., additional

Published
2010
Full Text
View/download PDF

47. A retrospective review of cancer treatments and outcomes among Inuit referred from Nunavut, Canada.

Author

Asmis, T. R., Febbraro, M., Alvarez, G. G., Spaans, J. N., Ruta, M., Lalany, A., Osborne, G., and Goss, G. D.

Subjects
*RETROSPECTIVE studies, *INUIT health, *SOCIOCULTURAL factors, *RADIOTHERAPY, *CANCER chemotherapy, OTTAWA Hospital (Ottawa, Ont.)
Abstract

Background Cancer is a health concern in Inuit populations. Unique cultural, dietary, and genetic factors and geographic isolation influence cancer epidemiology in this group. Inuit-specific data about oncology treatments and survival outcomes in Canadian Inuit referred to urban treatment centres are lacking. Methods A retrospective chart review of Inuit patients referred to The Ottawa Hospital Cancer Centre (TOHCC) from the Baffin region of Nunavut between 2000 and 2010 was conducted. Nunavut cancer registry data were used to establish the percentage of cancer cases referred and their survival outcomes. Results Of 307 cancer patients registered among Baffin-region Inuit, 216 [70% (63 men, 153 women)] were referred to tohcc for chemotherapy (CT) and radiation therapy (RT). Mean age in the referred group was 59.3 years (range: 25-89 years), and current smokers constituted half the group (52%). The cancers most commonly leading to referral in men were lung (55%), colorectal (19%), and nasopharyngeal (11%) cancers; in women, they were lung (46%), colorectal (24%), breast (10%), nasopharyngeal (6%), and cervical (5%) cancers. Of the 216 referred patients, 82 (38%) had already undergone surgery, and 18 (8%) received chemoradiation or RT only, all given with curative intent. Among the surgical patients referred, 33 (40%) and 23 (28%) went on to receive adjuvant CT and adjuvant RT respectively. Among 116 patients referred for palliative care, 64 (55%) received CT, 76 (66%) received RT, 43 (37%) received both CT and RT, and 19 (16%) received neither treatment. Median all-stage overall survival was 10 months for patients with lung cancer [95% confidence interval: 6.1 to 13.9 months] and 37 months for patients with colorectal cancer [95% confidence interval: 14.8 to 59.2 months]. Conclusions High uptake of palliative and adjuvant CT and RT was observed in the Inuit patients referred to TOHCC. Lung cancer was the most common cancer in referred Inuit men and women. The survival rates for Inuit lung cancer patients referred to TOHCC were comparable to those in the rest of Canada. Further research is required to understand reasons for non-referral of Canadian Inuit to TOHCC. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results